CELLINK launches the BIO MDX Series , a scaled-up revolution in biomedical manufacturing

"Leveraging synergies across the group, this launch represents an important step toward developing systems and solutions that bring CELLINK closer to patient care and creating the future of medicine. Biomedical manufacturing has desperately needed improved technologies, and the BIO MDX Series provides just that," says Héctor Martínez, CELLINK CTO.  " Leveraging synergies across the group, this launch represents an important step toward developing systems and solutions that bring CELLINK closer...
Comunicato Precedente

next
Comunicato Successivo

next
STOCKHOLM, (informazione.it - comunicati stampa - telecomunicazioni)

"Leveraging synergies across the group, this launch represents an important step toward developing systems and solutions that bring CELLINK closer to patient care and creating the future of medicine. Biomedical manufacturing has desperately needed improved technologies, and the BIO MDX Series provides just that," says Héctor Martínez, CELLINK CTO. 

"Bioprinting is increasing in stature within the life sciences. In order to grow with our customers, it is essential that we continue to push the industry forward and develop the latest and greatest technologies. The BIO MDX represents exactly this and goes a long way in strengthening what is already a robust bioprinting product portfolio," says Artur Aira, CELLINK Bioprinting Business Area Manager. 

For further information, please contact:

 Phone (US): +1 (650) 515 5566

Email: [email protected]   

Phone (US): +1 (857) 332 2138

Email: [email protected]

About CELLINK

Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK's products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/cellink-ab/r/cellink-launches-the-bio-mdx-series---a-scaled-up-revolution-in-biomedical-manufacturing,c3306652

The following files are available for download:

https://mb.cision.com/Main/14960/3306652/1387002.pdf

Release

https://news.cision.com/cellink-ab/i/cellink-product-launch-next-generation-bioprinter-bio-mdx,c2888783

CELLINK product launch Next generation bioprinter BIO MDX

 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/cellink-ab/r/cellink-launches-the-bio-mdx-series---a-scaled-up-revolution-in-biomedical-manufacturing,c3306652

The following files are available for download:

 

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Slide ShowSlide Show
Non disponibili